RF vs TNGX · rev $1.75B vs $5.36B cap
RF (RF) versus Tango Therapeutics Inc (TNGX) — a side-by-side from cached financials, not a winner call.
RF (RF) common stock.
Tango Therapeutics Inc (TNGX) is a biotechnology company listed on NASDAQ.
Latest reported RF revenue for 2026-06-30 was $1.75B. Net income was $570.0M. Revenue was up 2.7% from 2026-03-31 to 2026-06-30. RF currently screens at market cap $0.
Latest reported TNGX revenue for 2026-06-30 was $0. Net income was -$100.9M. TNGX currently screens at market cap $5.36B.
RF currently screens at market cap $0. TNGX currently screens at market cap $5.36B.
Not investment advice. Open the RF and TNGX stock pages for the full models.
Not investment advice.